PTX.AX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 14:10):

Stats
今日成交量	762 848
平均成交量	1.17M
市值	41.88M
EPS	$0 ( 2024-02-21 )
Last Dividend	$7.15 ( 1993-10-21 )
Next Dividend	$0 ( N/A )
P/E	-5.20
ATR14	$0.00100 (1.89%)

Prescient Therapeutics 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Prescient Therapeutics 财务报表

Annual	2023
营收:	$2.43M
毛利润:	$2.43M (99.91 %)
EPS:	$-0.00960

FY	2023
营收:	$2.43M
毛利润:	$2.43M (99.91 %)
EPS:	$-0.00960

FY	2022
营收:	$1.89M
毛利润:	$1.89M (99.93 %)
EPS:	$-0.00790

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.00680

Financial Reports:

No articles found.

Prescient Therapeutics Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Prescient Therapeutics Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$5.72	1990-10-25
Last Dividend	$7.15	1993-10-21
Next Dividend	$0	N/A
Payout Date	1993-12-31
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$12.87	--
Avg. Dividend % Per Year	0.00%	--
Score	0.22	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2026-10-05)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.22

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for ASX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
MXT.AX	Ex Dividend Knight	2023-08-31	Monthly	0.00%
WBC.AX	Ex Dividend Junior	2023-05-11	Annually	0.00%
EHL.AX	Ex Dividend Knight	2023-09-07	Sporadic	0.00%
PCG.AX	Ex Dividend Junior	2023-08-29	Annually	0.00%
ALU.AX	Ex Dividend Knight	2023-09-04	Semi-Annually	0.00%
GUD.AX	Ex Dividend Knight	2023-08-25	Semi-Annually	0.00%
RFF.AX	Ex Dividend Knight	2023-09-28	Quarterly	0.00%
BRG.AX	Ex Dividend Knight	2023-09-13	Semi-Annually	0.00%
KSL.AX	Ex Dividend Knight	2023-09-06	Semi-Annually	0.00%
SRV.AX	Ex Dividend Knight	2023-09-04	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-2.49	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.313	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-0.318	1.500	-4.65	-6.97	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	10.26	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	9.96	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	3.08	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	-0.00952	2.00	-0.00317	-0.00635	[0 - 30]
freeCashFlowPerShareTTM	-0.00952	2.00	-0.00476	-0.00952	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	1.000	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-3.71	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.126	0.800	-2.50	-1.996	[0.5 - 2]
Total Score				-0.920

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-5.51	1.000	-0.658	0	[1 - 100]
returnOnEquityTTM	-0.318	2.50	-2.99	-6.97	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.00952	2.00	-0.00317	-0.00952	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.00952	2.00	-0.00317	-0.00635	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-1.911	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-2.46	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.81

Prescient Therapeutics

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.